Medical countermeasure development and testing, animal model development, assay qualification/validation, regulated studies, GLP

Dr. Brasel's research focuses on the strategic planning and execution of preclinical studies that evaluate medical countermeasures (vaccines and therapeutics) toward licensure. His primary interests lie in the implementation of quality systems and regulatory processes in BSL-3 and BSL-4 laboratories to advance product development. Current projects include vaccine and therapeutic development and testing against filoviruses, including Ebola and Marburg viruses, and SARS-CoV-2, the causative agent of COVID-19. As a means to further advance the field of regulatory science in high biocontainment laboratories, Dr. Brasel is serving as co-Principal Investigator on a grant funded through the FDA entitled "Achieving Data Quality and Integrity in Maximum Containment Laboratories," now in its eighth year of funding (https://www.fda.gov/emergency-preparedness-and-response/mcmi-professional-development-activities/training-course-achieving-data-quality-and-integrity-maximum-containment-laboratories). Dr. Brasel's ultimate goal is FDA approval of high-profile medical countermeasures specific for biodefense-related and emerging diseases.

Search PubMed Database for Publications